Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)

Market Cap	3.34B
Revenue (ttm)	428.64M
Net Income (ttm)	61.83M
Shares Out	108.29M
EPS (ttm)	0.57
PE Ratio	53.75
Forward PE	n/a
Dividend	0.20 (0.65%)
Ex-Dividend Date	May 20, 2025

Volume	1,399,900
Average Volume	1,637,932
Open	30.40
Previous Close	30.33
Day's Range	30.28 - 31.28
52-Week Range	18.52 - 58.66
Beta	-1.97
RSI	51.60
Earnings Date	Aug 20, 2025

About SHE:301281

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of active pharmaceutical ingredients. It offers gliclazide, for the treatment of NIDDM; metformin hydrochloride used as an adjunct to diet and exercise in adult patients with NIDDM; isosorbide mononitrate for prevention of angina pectoris and treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction; isosorbide dinitrate to prevent angina pectoris due to coronary artery disease; mecobalamin for periphera...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2004
• Employees: 696
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301281

Financial Performance

In 2024, SHE:301281's revenue was 463.72 million, an increase of 3.60% compared to the previous year's 447.58 million. Earnings were 60.27 million, a decrease of -21.76%.